Merck steps up U.S. measles vaccine production with increased demand

Merck, the sole U.S. supplier of measles vaccines, said the increased demand was noticeable, but did not amount to a surge, and has not required a significant increase in distribution across the country."Despite what we've seen as a huge uptick in the number of cases ... the demand side of the equation hasn't been outstripping our underlying capacity," Merck Chief Marketing Officer Mike Nally, who also runs the firms Global Human Health business, said in an interview.The U.S. Centers for Disease